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Abstract: The fabrication and initial applications of nanobubbles (NBs) have shown   promising 
results in recent years. A small particle size is a basic requirement for ultrasound contrast-
enhanced agents that penetrate tumor blood vessel pores to allow for targeted imaging and 
therapy. However, the nanoscale size of the particles used has the disadvantage of weakening 
the imaging ability of clinical diagnostic ultrasound. In this work, we fabricated a lipid NBs 
contrast-enhanced ultrasound agent and evaluated its passive targeting ability in vivo. The 
results showed that the NBs were small (436.8 ± 5.7 nm), and in vitro ultrasound imaging 
suggested that the ultrasonic imaging ability is comparable to that of microbubbles (MBs). 
In vivo experiments confirmed the ability of NBs to passively target tumor tissues. The NBs 
remained in the tumor area for a longer period because they exhibited enhanced permeability 
and   retention. Direct evidence was obtained by direct observation of red fluorescence-dyed NBs 
in tumor tissue using confocal laser scanning microscopy. We have demonstrated the ability to 
fabricate NBs that can be used for the in vivo contrast-enhanced imaging of tumor tissue and 
that have potential for drug/gene delivery.
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Introduction
Tumors induce angiogenesis to increase their nutrient and oxygen supply, enabling their 
rapid growth.1 However, the blood vessels in tumors are leaky and defective, with large 
pore cutoff sizes, and the endothelial cells are misaligned or have large fenestrations.2 
Moreover, tumors have poor lymphatic drainage compared with normal tissues.2,3 All 
of these features allow for the delivery of drugs and gene carriers, such as liposomes, 
polymer micelles/vesicles and other macromolecules, to the tumor tissue; this ability 
is known as the enhanced permeability and retention (EPR) effect.4,5
The EPR effect of tumor blood vessels enables the design of targeted treatment 
options such as the use of small, negatively charged and PEGylated agents.6 One of the 
basic requirements for therapeutic or imaging agents to be able to leak through tumor 
pores for tumor-targeted therapy and imaging is a small particle size.
The application of microbubbles (MBs) in contrast-enhanced ultrasound (CEUS) has 
become an indispensable part of clinical ultrasonography,7 and molecular imaging via 
ultrasound has recently attracted significant attention.8 MBs help to enhance the speci-
ficity and sensitivity of imaging for various types of diseases, especially with tumors.9 
Other advantages of using MBs include a lower cost of contrast agents, an opportunity 
for real-time observation and the elimination of the exposure to radiation.10
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In the development of molecular imaging, the   fundamental 
enabling technology for ultrasonic molecular imaging is 
the targeted CEUS agent.11 However, compared with con-
trast agents for computed tomography (CT) and magnetic 
resonance imaging (MRI), MBs are much larger (2–8 µm). 
Therefore, when used in diagnostic ultrasound, MBs can 
become trapped in the blood pool after intravenous   injection. 
Consequently, most research on targeted MBs has been 
limited to studies involving diseases of the cardiovascular 
system, such as inflammation, arteriosclerosis, and thrombus 
formation.12–15 MBs pose severe limitations in tumor-targeted 
imaging due to their large diameters.
Recently developed nanoscale bubbles (nanobubbles 
[NBs]) are promising contrast agents for extravascular ultra-
sonic imaging. Nanoscale ultrasound contrast agents with 
various shells (polymers or phospholipids) and cores (gas, 
liquid, or solid) have been fabricated and exhibit good con-
trast enhancement. Based on several in vitro16–19 and in vivo20 
studies, phospholipid-shell and gas-core NBs have shown 
optimal contrast enhancement abilities. However, research on 
NBs is still in the initial stages.21,22 Moreover, in vivo studies 
have focused on the contrast enhancement abilities of these 
agents in only normal organs or in tumors, and their passive 
tumor-targeted potential has not yet been explored. Whether 
NBs can pass through the endothelial gaps of tumors and 
maintain a high imaging quality is unknown.
In this study, phospholipids were used to form the 
membrane for the fabrication of NBs, which then demon-
strated an ultrasonic imaging ability similar to that of MBs. 
  Scanning electron microscopy (SEM) was used to evaluate 
the morphology of the NBs. In vivo experiments confirmed 
the passive targeting ability of NBs in tumor tissues. The 
NBs remained in the tumor area for a longer period than 
MBs, and a high imaging quality was detected using in vivo 
tumor ultrasound imaging. Red fluorescent dye-labeled NBs 
were observed to remain in tumor tissues, as evaluated using 
confocal laser scanning microscopy, and this finding further 
supports the conclusion that NBs are passively targeted to 
tumor tissue.
Material and methods
Materials
The phospholipids used in the fabrication of the NBs included 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC; Mw, 
734.05), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[biotinyl(polyethylene glycol)2000] (PEG2000-DSPE; 
Mw, 3016.81) and 1,2-dipalmitoyl-sn-glycero-3-phosphate 
(DPPA; Mw, 670.88), which was in powder form (Avanti 
Polar Lipids Inc, Alabaster, AL) and used without further 
purification. Pluronic F-68 and glycerol were purchased from 
Sigma-Aldrich (St Louis, MO). Octafluoropropane (C3F8) gas 
was purchased from the R&D Center for Specialty Gases at 
the Research Institute of Physical and Chemical Engineering 
of Nuclear Industry (Tianjin, China). The fluorescent probes, 
DiI and Hoechst 33342, were purchased from Beyotime 
(Haimen, China).
Synthesis of the bubbles
NBs were prepared using a thin-film hydration-sonication 
method.22 Briefly, all phospholipids (18 mg DPPC, 3.5 mg 
PEG2000-DSPE, and 1 mg DPPA) were dissolved in 4 mL 
of chloroform (a small amount of the fluorescent membrane 
probe DiI was added for confocal laser scanning microscopy) 
and transferred into a 9-cm culture dish to form a thin phos-
pholipid film by natural evaporation in a fume hood. The mate-
rial was then hydrated with 4 mL of hydration liquid, which 
consisted of 10% glycerol (v/v) and 2 mg/mL Pluronic F-68, 
at 37°C in a shaking incubator for 1 hour to prepare   liposomes. 
The liposomal suspension was transferred to a 50-mL centri-
fuge tube, and the air above the liquid was replaced with C3F8 
gas using a long, fine needle and a 50-mL syringe. Finally, 
the 6-mm probe of a VCS 130 PB ultrasonic processor 
(Sonics and Materials Inc, Newtown, CT) was placed at the 
air–liquid interface, and the solution was sonicated at 130 W 
for 5 minutes to form the NBs (  Figure 1). Another sample of 
MBs was prepared as a control using the same formula, but 
without DPPA, Pluronic F-68, or glycerol.
The diameters of the bubbles varied widely (from 
100 nm to 3000 nm); thus, a purification of NBs between 
200 nm and 700 nm in diameter was necessary. A low-speed 
centrifugation (50 × g, 5 minutes) separated large bubbles 
from the suspension as a thin layer, which was discarded. 
Centrifugation at a higher speed (805 × g, 30 minutes) was 
performed after the suspension was transferred to a 15-mL 
centrifuge tube. Small NBs were collected after removing the 
lower liquid layer, which contained phospholipid fragments 
and liposomes. Finally, the NBs were resuspended in 4 mL 
phosphate-buffered saline (PBS) and stored at 4°C.
The NB and MB bubble concentrations were determined 
using a hemacytometer. A drop of DiI-labeled sample was 
transferred to a hemacytometer and observed using a Carl 
Zeiss Aviox-1 inverted fluorescence microscope (Carl Zeiss, 
Oberkirchen, Germany). A fluorescent compound, Dil, was 
used to detect bubbles that were not detectable at visible 
wavelengths. Three pairs of images (one fluorescent and 
one bright field image of each field) at different fields were 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
896
Yin et alInternational Journal of Nanomedicine 2012:7
acquired (400×). The boundary of each bubble-counting 
region was confirmed in the bright field image using the 
hemacytometer. The number of bubbles in each region was 
then counted using WCIF ImageJ software (v1.37; National 
Institutes of Health, Bethesda, MA). Finally, the concentra-
tion of the sample (bubbles/mL) was calculated using the 
same cell-counting method. All measurements were carried 
out in triplicate.
Particle-sizing and zeta potential 
measurements
The particle sizes were measured using dynamic light scat-
tering (DLS) with a laser wavelength of 660 nm at an angle 
of 90° using the 90Plus Multi-angle Particle Sizing Option 
(Brookhaven Instruments Corporation, Holtsville, NY). Ten 
microliters of sample and 90 µL of PBS were mixed in sample 
wells before measuring the particle sizes at 25°C. The zeta 
potential of each sample was measured using a Zeta Plus Ana-
lyzer (Brookhaven Instruments Corporation) to determine the 
electrophoretic light scattering at 25°C. All samples used for 
zeta potential measurements were prepared at the same con-
centration as those used for particle   sizing. The particle size 
and zeta potential of each sample were measured five times.
Scanning electron microscopy
To visualize the structure of the NBs, scanning electron 
microscopy (SEM) images were recorded. A drop of sample 
on a dust-free foil was placed in a desiccator. After the solvent 
evaporated, each sample was gold sputter-coated for 5   minutes. 
A field emission scanning electron microscope (JSM-6330F; 
JEOL, Tokyo, Japan) was used with a gun acceleration voltage 
of 3.0 kV and a working distance of 9.7 mm.
Biocompatibility tests
Cytotoxicity assay
To confirm good biocompatibility in vitro, we selected 
the mouse prostatic cancer cell line RM-1 to evaluate the 
cytotoxicity of the NBs using the MTT assay. All experiments 
were conducted in triplicate. The cells were seeded in 96-well 
plates at a density of 5000 cells/well and then cultured for 
24 hours in 100 µL of RPMI-1640 medium containing 10% 
fetal bovine serum (FBS) in a humidified atmosphere with 
5% CO2. The cells were then incubated for 24 hours in the 
same volume of fresh medium with various phospholipid 
concentrations (0.5–2500 µg/mL); the medium was then 
replaced with 100 µL of fresh medium containing 10 µL of 
MTT solution (5 mg/mL), and the cells were subsequently 
incubated for 4 hours. Dimethyl sulfoxide (100 µL) was 
added to dissolve the substrate after the MTT-containing 
supernatant was discarded. After gentle agitation for 
5   minutes, the absorbance of each well at 494 nm was 
recorded using an Infinite F200 multimode plate reader 
(Tecan, Männedorf, Switzerland).
Hemolysis test
Blood was obtained from the main abdominal artery of 
Sprague–Dawley rats and was collected in a tube that con-
tained heparin sodium (15 UI/mL). Each 4 mL of rat blood 
was mixed with 5 mL of normal saline. Then, 0.2 mL of 
blood diluent was added to 10 mL of normal saline as a 
negative control, and 0.2 mL of blood diluent was added to 
10 mL of double-distilled water as a positive control. The 
same erythrocyte concentration was used for all   phospholipid 
  concentrations (0.5–2500 µg/mL). The solutions were incu-
bated in a 37°C water bath for 1 hour. The degree of hemolysis   
DPPC
Thin-film C3F8 gas
H2O
core
C3F8 gas
core
Sonicated Hydration
Liposome Nanobubble DPPA
PEG-DSPE
Figure 1 Formation and structural transitions of nanobubbles for ultrasonic imaging and tumor targeting.
Abbreviations: DPPA, 1,2-dipalmitoyl-sn-glycero-3-phosphate; DPPC, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; PEG-DSPE, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[biotinyl(polyethylene glycol)2000].
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was determined spectrophotometrically at 540 nm using an 
Infinite F200 multimode plate reader (Tecan).
In vitro ultrasound imaging
To compare the ultrasonic imaging ability of the NBs with 
MBs, in vitro ultrasound imaging experiments were carried 
out; 1 mL of NB and MB suspension at various bubble 
concentrations (from 1.0 × 105 to 6.4 × 106 bubbles/mL) 
was added to the sample wells of a custom-made 2% 
(w/v) agarose mold (Figure 2). Another sample of NB at 
the concentration of 8.0 × 105 bubbles/mL was exposed to 
high-power ultrasound (1 MHz, 0.78 W/cm2) for 30 seconds 
by using a self-made low-frequency therapeutic ultrasound 
system (Chongqing, China) for NB destruction experiment. 
A clinical ultrasound scanner (Acuson Sequoia 512; Siemens, 
Malvern, PA) system with a 15 L8-S high-frequency linear 
transducer was used. The transmitted power was -18 db, 
which corresponded to an MI of 0.10. The contrast pulse 
sequencing (CPS) gain was 0 db, and the focal zone was 
placed at a depth of 1.5 cm, which was at the center of the 
sample well. Three images were taken for each sample.
Image analysis was performed using ImageJ software to 
analyze the gray-scale values of the samples. Circular regions 
of interest (ROIs) were outlined in each sample well. The 
quantitative grey-scale ultrasonic intensity of the samples 
was normalized to that of gas-free water. The intensity value 
was defined as the gray-scale value ratio of contrast agent 
to gas-free water.
In vivo contrast-enhanced ultrasound 
imaging
The in vivo imaging capability of the NB contrast agents 
was evaluated using Sprague–Dawley rats. Each rat was 
anesthetized with 300 mg/kg of 10% chloral hydrate by 
  intraperitoneal injection. The animals were placed on a warm 
blanket to maintain their body temperature within normal 
range. The NB samples (109 bubbles/mL) were intravenously 
injected at a dosage of 0.1 mL/kg. Various organs, such as 
the heart, liver and kidneys, were imaged transabdominally 
using a broadband 15L8-S high-frequency linear transducer 
in CPS mode with an MI of 0.19. All animal experiments were 
carried out in accordance with the procedures and guidelines 
of the Institutional Animal Care and Use   Committee and 
were approved by the Animal Experiment Committee and 
Biosafety Committee at Sun Yat-Sen University of Medical 
Science.
In vivo passive tumor-targeting ability
RM-1 cells were transplanted into BALB/c nude mice for 
passive tumor-targeting imaging experiments. The cells 
were cultured in RPMI-1640 medium supplemented with 
10% FBS (GIBCO, Carlsbad, CA) and incubated at 37°C 
in a humidified atmosphere of 5% CO2 in air. A total of six 
BALB/c nude mice (5 weeks, 18–23 g) were examined. The 
cells (106) were resuspended in 0.1 mL of PBS and subcutane-
ously injected into the dorsal scapular area on the right side 
for tumor xenografts. All in vivo experiments began when 
the tumors reached a diameter of 0.8–1.2 cm.
Mice were anesthetized with 10% chloral hydrate and 
fixed on a plate before ultrasonic imaging. The ultrasonic 
transducer was fixed on an iron support stand. The distance 
between the transducer and the tumor was approximately 
2 cm, and the space between them was filled with an adequate 
quantity of ultrasonic transmission gel. MBs and NBs were 
used in the same mice to compare the performance of NBs 
to that of MBs. MBs (6.0 × 106) were suspended in 50 µL of 
PBS and injected into the tail vein. Ultrasonic images were 
acquired using a 7-MHz transducer in CPS mode, and the 
acoustic focal zone was placed at the center of the tumor at the 
largest transverse cross-section. A 10-minute CPS imaging 
sequence was acquired, and further images were recorded 
every 30 seconds for 1.5 hours. After the MB experiments, 
the bubbles were allowed to clear from the circulation of the 
mouse for 2 hours. Finally, the NBs were studied using the 
same bubble concentration and imaging protocol.
All digital clips and images were stored for offline 
  examination. Gray-scale images were analyzed using ImageJ. 
The quantitative gray-scale ultrasonic intensity of each image 
was defined as the ratio of post-contrast agent injection to 
pre-contrast agent injection. A time–intensity curve for each 
mouse was created, and three important parameters were 
Agarose mold
(top view) Screen Samples
Sample
wells
Transducer
Figure 2 Custom-made 2% (w/v) agarose mold for use with in vitro ultrasound 
imaging and the in vitro experimental setup.
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analyzed statistically: time to peak (TTP), peak intensity 
(PI), and half-time of washout (HT).
Confocal laser scanning microscopy 
examination
To confirm that the NBs were small enough to pass through 
the endothelial gaps of tumors, we used confocal laser scan-
ning microscopy (CLSM) to determine the location of red 
fluorescently dyed NBs in vivo; this technique is regarded 
as the gold standard. Tumor-carrying mice were randomly 
separated into two groups: NB and MB injection. A total of 
250 µL (2.5 × 107 bubbles/mL) of DiI-labeled NBs or MBs 
were injected into the tail vein of each mouse. To clear the 
labeled bubbles from circulation, the heart was perfused with 
0.9% normal saline 3 hours after bubble injection. The tumors 
and muscles of the right thigh (used as negative controls 
because the capillaries of skeletal muscle are   continuous) 
were immediately extracted for sectioning into 5-µm slices. 
Frozen sections were stained in a solution of 2 µg/mL 
Hoechst 33342 for 30 minutes to mark the nucleus. Images 
were recorded using an Olympus PV1000-IX81   Confocal 
Microscope (Olympus, Tokyo, Japan). DiI and Hoechst 
33342 were excited at 550 and 352 nm, respectively, and the 
emissions were recorded at 565 and 455 nm, respectively.
Statistical analysis
The unpaired Student’s t-test was performed for all 
  comparisons. All data are expressed as the mean ± the 
standard errors of the mean (SEM). The data were statisti-
cally analyzed with SPSS software (version 13.0; SPSS 
Inc, Chicago, IL) using one-factor analysis of variance. 
A P value , 0.05 was considered statistically significant. 
All statistical tests were two-tailed.
Results
Characterization of the bubbles
The average diameter of the nanoscale ultrasound contrast 
agent (NBs) was 436.8 ± 5.7 nm (n = 5) (Figure 3A), and that 
of the control MBs was 1220 ± 65 nm (n = 5) (Figure 3B). 
Zeta potential measurements showed that the NBs had a net 
negative charge of -18.36 ± 0.81 mV (n = 5), while that of the 
MBs was -2.93 ± 0.42 mV (n = 5). The bubble concentrations 
of the NBs and MBs were (1.22 ± 0.16) × 109 bubbles/mL 
(n = 3) and (5.64 ± 0.19) × 108 bubbles/mL (n = 3), respec-
tively. The negative charge was due to the presence of the 
anionic phospholipid DPPA, which helped to avoid physical 
aggregation of the bubbles and restricted the size of the NBs. 
Surface morphology and size distribution were viewed using 
SEM (Figure 3C), and the results showed that the NBs were 
small, spherical, and nonaggregating. The size distribution 
of the NBs was between 250–500 nm, which was similar to 
that measured using DLS.
Biocompatibility tests
The cytotoxicity of the NBs was evaluated using the MTT 
assay and the mouse prostatic cancer cell line RM-1. 
  Figure 4 shows the cytotoxicity of the NBs after incuba-
tion for 24 hours. The MTT results indicate that the NBs 
had no obvious cytotoxicity toward this cell line within 
the concentrations used for in vivo ultrasound imaging 
with phospholipids (0.5–5 µg/mL). At higher phospholipid 
concentrations (higher than 10 µg/mL), their cytotoxicity 
increased rapidly. In vitro hemolysis tests were carried out 
spectrophotometrically. As shown in Figure 4, the presence 
of lower concentrations of NBs had no effect on the rate 
of hemolysis. However, at phospholipid concentrations 
higher than 50 µg/mL, hemolysis occurred in a dose-
dependent manner.
In vitro and in vivo contrast enhancement 
abilities of NBs
Ultrasound images were acquired at various bubble con-
centrations (Figure 5A) using diagnostic high-frequency 
ultrasound (7 MHz). The results showed that as the 
bubble concentration increased, the ultrasonic signals 
of both the NBs and MBs increased. NBs exhibited an 
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ultrasonic   contrast enhancement ability similar to that of 
MBs (Figure 5B). No statistical differences were observed 
between the signal enhancement from NBs and that of 
MBs (P = 0.134). After high-power ultrasound exposure, 
gray-scale intensity decreased as NBs were destroyed 
(Figure 5C).
In the in vivo studies, CPS-mode gray-scale images were 
obtained before and after the administration of NB contrast 
agent to Sprague–Dawley rats (Figure 6). The heart, liver, 
and kidneys showed excellent enhancement several seconds 
after intravascular administration of the NBs.
Imaging of tumors based on passive 
tumor targeting
CPS-mode imaging was carried out on six tumor-carrying 
mice. No animals died during the experiment. Figure 7 shows 
a representative set of images of the contrast enhancement 
provided by NBs (Figure 7A) and control MBs (Figure 7B) 
over time (0, 0.5, 1, 5, 10, and 15 minutes). The tumor 
imaging results showed that the NBs considerably improved 
contrast enhancement. The enhancement obtained using NBs 
lasted for approximately 1 hour, whereas that obtained using 
the control MBs lasted for only 15 minutes. At 15 minutes 
after injection, the gray-scale intensity of the NBs was sig-
nificantly higher than that of the control MBs (P , 0.001).
Representative time–intensity curves show the increases 
in the contrast ratio of the intensity produced by the NBs and 
control MBs over time (Figure 7C). The slope of the NB line 
is less steep than that of the control MB line. With the NBs, 
the TTP was later (P = 0.015), the PI was lower (P = 0.027), 
and the HT was longer (P = 0.001) than the corresponding 
values for the control MBs (Table 1).
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CLSM experiments
Under CLSM, the distributions of the DiI-labeled NBs or 
MBs in the frozen sections of the tumors and skeletal muscle 
were apparent (Figure 8). In tumors, a considerable number 
of DiI-labeled NBs were present in the intercellular space 
(Figure 8A), whereas the NBs could barely be observed in 
skeletal muscle sections (Figure 8C). In the control, rare DiI-
labeled MBs were observed in tumors and skeletal muscle 
(Figure 8B and D).
Discussion
Recently, nanoscale ultrasound contrast-enhanced agents 
with various shells (polymers or phospholipids) and cores 
(gas, liquid, or solid) have been fabricated. Good contrast-
enhanced effects have been observed in a number of reported 
studies, and phospholipid-shell and gas-core NBs have shown 
optimal contrast-enhancing abilities.16–19 However, studies in 
vivo have focused on the contrast enhancement abilities of 
these agents in normal organs or tumors, not on the potential 
of NBs for the passive targeting of tumors. As a result, the 
purpose of this work was to fabricate nanosized, phospholipid-
shelled NBs with high ultrasonic-imaging efficiency and of 
a sufficiently small size to pass through the pores of tumor 
vasculature and achieve passive tumor targeting. Herein, NBs 
that were demonstrated to have small diameters using DLS 
and SEM were evaluated for their ultrasound imaging ability 
in vitro and their delayed imaging ability in tumor tissues.
A key factor in producing small NBs was the presence of 
Pluronic F-68, which stabilizes the NBs, controls their size, 
and interacts with lipid shells to change the lipid fluidity or 
bubble elastic modulus.22 One of the components, the anionic 
phospholipid DPPA, equipped the NBs with negatively 
charged membranes to avoid aggregation and enhance the 
stability of the bubbles due to electrostatic repulsive forces. 
SEM is the gold standard for determining the diameter 
distribution and morphology of NBs. The results of SEM 
and DLS showed that the NBs were small (,500 nm) and 
spherical, which implies that the small NBs with the large 
bubbles removed responded well to ultrasound.
The NBs were composed of phospholipids that are used 
in the cell cytomembrane and are known to be low-toxicity 
Heart
Kidney
Liver
Figure 6 Contrast pulse sequencing-mode images of various organs of normal rats. 
Images after nanobubble injection (right) showed obvious contrast enhancement 
in the heart, kidney and liver of Sprague–Dawley rats compared with preinjection 
images (left).
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materials. The results of the MTT assay and the hemolysis 
test, which were used to determine the cytotoxicity of the 
NBs, confirmed their biological safety. At commonly used 
phospholipid concentrations, the NBs were safe for use in 
cell studies and in vivo ultrasound imaging.
The NBs exhibited similar echogenic ability to the control 
MBs in vitro using high-frequency diagnostic ultrasound. 
This similarity likely resulted from two factors. First, lipid 
shells are easier to form and yield a very echogenic and 
elastic bubble.23 Highly compressible shells play an impor-
tant role in the echogenicity of NBs by allowing high scat-
tering.24   Second, the CPS mode of the Sequoia 512 scanning 
instrument is not only a harmonic imaging mode, but also a 
summation of corresponding echoes from three pulses with 
different amplitudes and phases.25 Although the resonant fre-
quency of the NBs was much higher than that of the clinical 
diagnostic ultrasound, the high scattering may enhance the 
acoustic imaging impact of these NBs.
The results of in vivo ultrasonic experiments used to 
examine the passive targeting imaging of tumors suggested 
that NBs are retained in the tumor tissue for longer periods 
than MBs. All parameters of the time–intensity curve sup-
ported the imaging results. The TTP was later (P = 0.015), the 
PI was lower (P = 0.027), and the HT was longer (P = 0.001) 
in the NB group than the corresponding values for the con-
trol MB group in tumor areas; all of these results stemmed 
from the small size of the NBs. First, the small diameter 
helped the bubbles to permeate the tumor vasculature and 
remain in the tumor tissue.1 As time passed, greater num-
bers of NBs passed through the endothelial gaps and were 
retained. This allowed the echogenicity to remain strong 
for much longer periods than the MBs, which were almost 
cleared after 10 minutes. Second, some time is necessary for 
the permeation and aggregation of the NBs; this requirement 
explains why the TTP of the NBs was later than that of the 
control MBs, which were too large to fit through the endothe-
lial gaps. Third, because of their small size, the NBs were 
expected to absorb high-frequency ultrasound to a greater 
degree than their scattering at the fundamental frequency;26 
thus, the NBs exhibited a lower peak intensity in this study. 
Finally, their small size and PEGylated lipid shells helped the 
NBs escape from the mononuclear phagocyte system.27,28
CLSM imaging revealed the location of the NBs after 
intravenous injection. The majority of tumors have a pore 
cutoff size between 380 and 780 nm,16,29 which is the founda-
tion of the molecular imaging of tumors using passive tumor 
targeting.30 In the present study, DiI-labeled NBs penetrated 
through interendothelial gaps and accumulated in the tumor, 
and red fluorescence was observed in the images. However, 
Table 1 Quantitative parameters of NBs and MBs in in vivo 
tumor ultrasound imaging (mean ± SEM)
TTP (seconds) PI (ratio) HT (seconds)
NBs 165.0 ± 15.1 6.9 ± 0.8 1265.0 ± 60.3
MBs 24.2 ± 2.5 8.4 ± 0.7 310.0 ± 20.7
t 3.660 -3.096 7.222
P 0.015 0.027 0.001
Abbreviations: HT, half-time to washout; MBs, microbubbles; NBs, nanobubbles; 
PI, peak intensity; SEM, scanning electron microscopy; TTP, time to peak.
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Figure 8 Confocal laser-scanning microscopy images of frozen sections after nuclear labeling. A considerable number of DiI-labeled nanobubbles are observed in the intercellular 
space (A), whereas DiI-labeled microbubbles are hardly visible in tumors (B). Both DiI-labeled nanobubbles and microbubbles were difficult to detect in skeletal muscle (C and D).
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the MBs were absent from the tumor tissue as demonstrated 
by the almost complete absence of DiI red fluorescence. 
These phenomena could explain the ultrasonic imaging per-
formance. At the later stage of ultrasound contrast-enhanced 
imaging, NBs passed through the pores in tumor vessels and 
accumulated in the tumor; therefore, the contrast enhance-
ment remained for a much longer period than when using 
the MBs, which do not pass through. The inter-endothelial 
gaps of normal tissue are less than 7 nm,31 and neither NBs 
nor MBs can pass through gaps of this size. As a result, there 
was passive targeting of the NBs to tumors.
Conclusion
The basic requirement of tumor imaging and targeting by 
ultrasound is that the particle size of the ultrasound contrast-
enhanced agents be small. However, a nanoscale particle size 
reduces the ultrasonic imaging ability in clinical diagnostic 
ultrasound applications. How this contradiction is solved to 
realize tumor targeting is an important topic in the use of 
ultrasound in molecular imaging. In this work, we fabricated 
a nano-sized lipid NB contrast-enhanced ultrasound agent 
and evaluated its echogenic ability in vitro and in vivo. Its 
ability to passively target tumors was confirmed by in vivo 
ultrasonic imaging and CLSM. Their characteristics suggest 
that NBs may be applicable to ultrasonic molecular imaging 
and tumor-targeting therapy. Potential applications for NBs 
include contrast-enhanced imaging and drug/gene delivery 
to tumors.
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